Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Veridien launches new product for flu season
Veridien, whose focus is on infection control and healthy lifestyle products, will market the new line in 434 Canadian retail stores. It is intended that the Virguard product
Veridien, whose focus is on infection control and healthy lifestyle products, will market the new line in 434 Canadian retail stores. It is intended that the Virguard product
The expanded indication now includes patients with a first clinical event suggestive of multiple sclerosis (MS). This approval provides patients in Australia with the potential to delay the
The approval is for the administration of Keppra is as an adjunctive therapy in the treatment of primary generalized tonic-clonic seizures in adults and adolescents from 12 years
Teva’s ondansetron product is the generic equivalent of GlaxoSmithKline’s antiemetic Zofran injection. Teva believes that its generic equivalent will save customers money as Zofran is one of the
A US district court denied the injunction brought by a unit of Johnson & Johnson, Ortho Biotech. The company claims that Amgen’s discount prices are leading to failing
Sprycel is also indicated for the treatment of adults with Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia (ALL) and lymphoid blast chronic myeloid leukemia (CML) with resistance or
“Our European customers can now use treatment systems for both platelets and plasma that rely on the same instrument for processing. This is a compelling operational benefit to
Currently, the authorized generic product will be distributed in the 25mg dosage strength. This agreement does not affect the availability of AstraZeneca’s branded version of metoprolol succinate, Toprol-XL.
Under the terms of the transaction, Anesiva will sell seven million shares of its common stock at a price of $6.40 per share, which represents no discount to
In a clinical trial, researchers evaluated the safety of using a gene vector, in this case an adeno-associated virus, to deliver a corrective gene to patients who are